Skip to main content

Advertisement

SpringerLink
Log in

Comparison of Aspirin and Naoxintong Capsule (脑心通胶囊) with Adjusted-Dose Warfarin in Elderly Patients with High-Risk of Non-Valvular Atrial Fibrillation and Genetic Variants of Vitamin K Epoxide Reductase

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To compared the therapeutic effect of a Chinese patent medicine Naoxintong Capsule (脑心通胶囊, NXT) and aspirin with adjusted-dose warfarin in Chinese elderly patients (over 65 years) with nonvalvular atrial fibrillation (NVAF) and genetic variants of vitamin K epoxide reductase (VKORC1), who are at high-risk of thromboembolism.

Methods

A total of 151 patients, with NVAF and AA genotype of VKORC1-1639 (a sensitive genotype to warfarin) and a CHA2DS2-VASc clinical risk score of 2 or above, were chosen for this study. Patients were randomized into two groups and orally treated with a combination of aspirin (100 mg/day) and NXT (1.6 g thrice a day) or adjusted-dose warfarin [international normalized ratio 2.0–3.0). The primary end points including ischemic stroke and death as well as the secondary end points including hemorrhage events were followed up for at least 1 year.

Results

Baseline clinical data and the rates of primary end points were similar between groups. However, the rate of serious bleeding (secondary event) in the combination therapy group was lower than that in the adjusted-dose warfarin group (0% vs. 7.9%, odds ratio: 0.921, 95% confidence interval: 0.862–0.984, P=0.028).

Conclusions

Aspirin combined with NXT and warfarin displayed comparable rates of primary end point including ischemic stroke and all-cause death during the 1-year follow-up. However, as compared with warfarin, the combination therapy reduced the rate of serious bleeding. Therefore, aspirin combined with NXT might provide an alternative pharmacotherapy in preventing ischemic stroke for elderly patients with NAVF who cannot tolerate warfarin. (No. ChiCTR-TRC-13003596)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949–953.

    Article  PubMed  Google Scholar 

  2. Dayi H, Yihong S, Ziqiang Z, Kuibao L, Yongbin N, Guang Y, et al. The case-control study of the risk factors of stroke in Chinese people with non-valvular atrial fibrillation. J Intern Med 2003;42:157–161.

    Google Scholar 

  3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–867.

    Article  PubMed  Google Scholar 

  4. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505–1511.

    Article  Google Scholar 

  5. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med 1997;157:1237–1240.

    Article  Google Scholar 

  6. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, et al; ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369–2429.

    Article  Google Scholar 

  7. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1–e76.

    Article  PubMed  Google Scholar 

  8. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005;14:1745–1751.

    Article  PubMed  CAS  Google Scholar 

  9. Gao Q, Fu X, Wei JW, Chen X, Huang Y, Wang J, et al. China QUEST Study Investigators. Use of oral anticoagulation among stroke patients with atrial fibrillation in China: the China QUEST (Quality evaluation of stroke care and treatment) registry study. Int J Stroke 2013;8:150–154.

    Article  PubMed  Google Scholar 

  10. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137:263–272.

    Article  PubMed  Google Scholar 

  11. Zhang WP, Chen H, Luo J, Wu XY. Influence of CYP2C9 1061 A/C and VKORC1 1639 G/A polymorphisms on waffarin dose. J Med Mol Bid 2007;4:396–400.

    CAS  Google Scholar 

  12. Lee SC, NG SS, Oldnburg J, Chong PY, Rost S, Guo JY, et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 2006;79:197–205.

    Article  PubMed  CAS  Google Scholar 

  13. Zheng LF, Chen H. Investigation of anticoagulation therapy for elderly patients with high risk of nonvanular atrial fibrillation. Clin J Clin (Electr ed) 2012;6:874–878.

    Google Scholar 

  14. Su L, Li Y, Lv B, Ji H, Ding H, Hu L, et al. Clinical study on Naoxintong capsule for stroke recovery of qi-deficiency and blood-stasis syndrome. China J Chin Mater Med (Chin) 2011;36:1530–1533.

    Google Scholar 

  15. Wang J, Chu FY, Li J, Yao KW, Zhong JB, Zhou KH, et al. Study on syndrome element characteristics and its correlation with coronary angiography in 324 patients with coronary heart disease. Chin J Integr Med 2008;14:274–280.

    Article  PubMed  CAS  Google Scholar 

  16. Tian JF, Li JD, Lei Y. Clinical features of acute myocardial infarction inpatients in 26 level three class A Chinese medicine hospitals in China and the investigation of treatment. Chin J Integr Tradit West Med (Chin) 2012;32:329–332.

    Google Scholar 

  17. Chen BJ, Pan ZQ, Su XX. Study on changes of TCM syndrome in patients with coronary heart disease before and after intervention treatment. Chin J Integr Tradit West Med (Chin) 2007;27:689–691.

    Google Scholar 

  18. Lardizabal JA, Joshi BK, Ambrose JA. The balance between anti-ischemic efficacy and bleeding risk of antithrombotic therapy in percutaneous coronary intervention: a yin-yang paradigm. J Invasive Cardiol 2010;22:284–292.

    PubMed  Google Scholar 

  19. Zhang H, Wang WR, Lin R, Zhang JY, Ji QL, Lin QQ, et al. Buyang Huanwu Decoction ameliorates coronary heart disease with qi deficiency and blood stasis syndrome by reducing CRP and CD40 in rats. J Ethnopharmacol 2010;130:98–110.

    Article  PubMed  Google Scholar 

  20. Zhou GY, Hu XQ, Chen XH, Su XW, Qu PX. Experimental study on effect of Buchang Naoxintong containing serum for antagonizing hypoxia-induced apoptosis of cortical neurons. Chin J Integr Tradit West Med (Chin) 2007;27:835–838.

    Google Scholar 

  21. Chen D, Lu P, Zhang FB, Tang SH, Yang HJ. Molecular mechanism research on simultaneous therapy of brain and heart based on data mining and network analysis. Chin J Integr Tradit West Med (Chin) 2013;38:91–98.

    CAS  Google Scholar 

  22. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005;14:1745–1751.

    Article  PubMed  CAS  Google Scholar 

  23. Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015;365: 2280–2287.

    Article  CAS  Google Scholar 

  24. Wang C, Yang Z, Wang C, Wang Y, Zhao X, Liu L, et al. Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the china national stroke registry. J Stroke Cerebrovasc Dis 2014;23:1157–1163.

    Article  PubMed  Google Scholar 

  25. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029–2037.

    Article  PubMed  CAS  Google Scholar 

  26. Mega JL, Close SL, Wiviott SD. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354–362.

    Article  PubMed  CAS  Google Scholar 

  27. Chen H, Yan W, Wu XY, Luo JW, Li CD. Relationships of blood stasis syndrome, CYP2C19 gene polymorphism with clopidogrel resistance and post-PCI prognosis. Chin J Integr Tradit West Med (Chin) 2010;30:1245–1249.

    Google Scholar 

  28. Jang JS, Cho KI, Jin HY, Seo JS, Yang TH, Kim DK, et al. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol 2012;110:502–508.

    Article  PubMed  CAS  Google Scholar 

  29. SJ Connolly, MD Ezekowitz, S Yusuf, the RE-LY Steering Committee and Investigators, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–1151.

    Article  PubMed  CAS  Google Scholar 

  30. MR Patel, KW Mahaffey, J Garg, the ROCKET AF Investigators, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–891.

    Article  PubMed  CAS  Google Scholar 

  31. CB Granger, JH Alexander, JJ McMurray. the ARISTOTLE Committees and Investigators, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–992.

    Article  PubMed  CAS  Google Scholar 

  32. RP Giugliano, CT Ruff, E Braunwald, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–2104.

    Article  PubMed  CAS  Google Scholar 

  33. Chen DK, Zhang HQ, Zhang JH. Intervening effect of Naoxintong on anti-platelet treatment with aspirin. Chin J Integr Tradit West Med (Chin) 2008;28:843–846.

    Google Scholar 

  34. Chen C, Venketasubramanian N, Gan RN, Lambert C, Picard D, Chan BP, et al. Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery. Stroke 2009;40:859–863.

    Article  PubMed  Google Scholar 

  35. Chen DK, Zhang HQ, Zhang JH. Intervening effect of Naoxintong on anti-platelet treatment with aspirin. Chin J Integr Tradit West Med (Chin) 2008;28:843–846.

    Google Scholar 

  36. Huang MW, Wang H, Zhong WJ, Wu XY, Chen H. Chinese herbal medicine Naoxintong Capsule combined with dual antiplatelet therapy in a rat model of coronary microembolization induced by homologous microthrombi. J Chin Integr Med (Chin) 2011;9:38–48.

    Article  Google Scholar 

  37. Wang H, Zhong WJ, Huang MW, Wu XY, Chen H. Efficacy of dual antiplatelet therapy combined with Naoxintong Capsules following coronary microembolization induced by homologous microthrombi in rats. Chin J Integr Med 2011;17:917–924.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Fujian Provincial Cardiovascular Disease Institute, Provincial Clinical College of Fujian Medical University, Fuzhou, 350001, China

    Huan Wang, Xiao-ying Wu & Hui Chen

  2. Cardiovascular Internal Medicine, Quzhou People’s Hospital of Zhejiang Province, Quzhou, Zhejiang Province, 324000, China

    Xiao-kai Zhou

  3. Cardiovascular Internal Medicine, the Affiliated Hospital in Putian College of Fujian Province, Putian, Fujian Province, 351100, China

    Li-fan Zheng

Authors
  1. Huan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiao-kai Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li-fan Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiao-ying Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hui Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hui Chen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, H., Zhou, Xk., Zheng, Lf. et al. Comparison of Aspirin and Naoxintong Capsule (脑心通胶囊) with Adjusted-Dose Warfarin in Elderly Patients with High-Risk of Non-Valvular Atrial Fibrillation and Genetic Variants of Vitamin K Epoxide Reductase. Chin. J. Integr. Med. 24, 247–253 (2018). https://doi.org/10.1007/s11655-015-2443-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-015-2443-4

Keywords

Search

Navigation